Interactive Video Lecture
Challenges and Opportunities in the Management of HER2+ Metastatic Breast Cancer
Release Date: March 8, 2022
Expiration Date: March 7, 2023
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
Program Overview
Program Description
Targeted therapies have improved disease control and overall survival in patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer, but integrating these agents into the clinic remains challenging. Oncology/hematology APPs need information on selecting therapies to optimize outcomes in patients with brain metastases, sequencing regimens, and educating patients about and managing toxicities. This video lecture features expert recommendations on using predictive biomarkers to guide use of targeted therapies and reviews monitoring for and managing toxicities associated with these agents.
Format
Interactive video lecture
Learning Objectives
After completing this activity, participants should be better able to:
- Summarize healthcare disparities in breast cancer and their potential impact on treatment and outcomes
- Identify appropriate therapies for patients with HER2-positive breast cancer based on clinical trial evidence, guideline recommendations, and patient and disease factors
- Use recommended strategies to identify and manage adverse events of novel therapies for HER2-positive breast cancer
- Apply current recommendations for cancer treatment during the COVID-19 pandemic, including COVID-19 vaccinations
Target Audience
Oncology NPs, PAs and nurses
Faculty
Sara A. Hurvitz, MD
- Professor of Medicine
- Director
- Breast Cancer Clinical Trials Program
- Division of Hematology/Oncology
- David Geffen School of Medicine
- Medical Director
- Clinical Research Unit
- Jonsson Comprehensive Cancer Center
- University of California, Los Angeles
- Los Angeles, California
Stephanie Andrews, MS, APRN-C
- Nurse Practitioner
- Department of Malignant Hematology
- H. Lee Moffitt Cancer Center and Research Institute
- Tampa, Florida
Details
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until March 7, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program is cosupported by educational grants from Gilead Sciences, Inc. and Seagen Inc.
This activity is supported by an educational grant from Seagen Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Andrews: fees for non-CME/CE services: Genentech.
Dr Hurvitz: contracted research: Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Cytomx, Daiichi Sankyo, Dignitana, Eli Lilly, Genentech/Roche, Gilead, GlaxoSmithKline, Immunomedics, Macrogenics, Novartis, Pfizer, OBI Pharma, Phoenix Molecular Designs, Ltd, Pieris, Puma Biotechnology, Radius, Sanofi, Seagen, Zymeworks.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Review the content in its entirety
- Relate the content material to the learning objectives
- Complete the evaluation form
The estimated time to complete this activity is 1.00 hour.
Release date: March 8, 2022
Expiration date: March 7, 2023
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 103521BCBC-7B